Decreased antistereotypic effect of neuroliptics after additional treatment with a benzodiazepine, a GABA agonist or an anticholinergic compound.
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D014150:Antipsychotic Agents / Q000037:antagonists & inhibitors*; D001519:Behavior / Q000187:drug effects*; D003975:Diazepam / Q000494:pharmacology; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000037:antagonists & inhibitors / Q000494:pharmacology; D051379:Mice; D010276:Parasympatholytics / Q000494:pharmacology*; D012601:Scopolamine / Q000494:pharmacology; D013239:Stereotyped Behavior / Q000187:drug effects*; D005680:gamma-Aminobutyric Acid / Q000502:physiology*
D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D010276:Parasympatholytics; D008774:Methylphenidate; D005680:gamma-Aminobutyric Acid; D012601:Scopolamine; D003975:Diazepam